Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia

BACKGROUND: The most advanced dengue vaccine candidate is a live-attenuated recombinant vaccine containing the four dengue viruses on the yellow fever vaccine backbone (CYD-TDV) developed by Sanofi Pasteur. Several analyses have been published on the safety and immunogenicity of the CYD-TDV vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorigatti, Ilaria, Aguas, Ricardo, Donnelly, Christl A., Guy, Bruno, Coudeville, Laurent, Jackson, Nicholas, Saville, Melanie, Ferguson, Neil M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504002/
https://www.ncbi.nlm.nih.gov/pubmed/26051515
http://dx.doi.org/10.1016/j.vaccine.2015.05.059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4504002/
https://www.ncbi.nlm.nih.gov/pubmed/26051515
http://dx.doi.org/10.1016/j.vaccine.2015.05.059

Ejemplares similares